Edition:
United Kingdom

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,504JPY
6:00am GMT
Change (% chg)

¥78 (+3.24%)
Prev Close
¥2,426
Open
¥2,470
Day's High
¥2,528
Day's Low
¥2,460
Volume
3,468,400
Avg. Vol
2,263,010
52-wk High
¥2,730
52-wk Low
¥2,185

Latest Key Developments (Source: Significant Developments)

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

National Investments Fund - Celyad enters into license agreement with ono pharmaceutical co., ltd. to develop allogeneic nkr-2 t-cell immunotherapy<1227.HK><4528.T>
Wednesday, 13 Jul 2016 

National Investments Fund Ltd <1227.HK>: Celyad enters into license agreement with Ono Pharmaceutical Co., Ltd. to develop allogeneic nkr-2 t-cell immunotherapy . Celyad would receive upfront payment of $12.5 million and is eligible of up to $299 million in development and commercial milestones . Celyad would also receive double digit royalties based on net sales of the licensed product in ono's territories . Under the agreement, Celyad would continue developing its allogeneic nkr-2 t-cell immunotherapy in EU and US territories . Says company is aware that Celyad s.a had published a press release on 11 July 2016 .  Full Article

Celyad says early signing agreement with ONO is because of interest of companies - conf call
Monday, 11 Jul 2016 

Celyad SA : Reason for early signing agreement with ONO Pharmaceutical <4528.T> is because of interest of companies to do so - conf call . In order for deal in US or Europe, would have to be "extremely compelling" for us at this stage - conf call . Within next 12 months we should expect second milestone - conf call . Royalty rate is same for all 3 countries - conf call . On C-Cure: discussions with EMA in Q3 - conf call . Japanese partnership has been relatively expedited - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Celyad enters into license agreement with ONO Pharmaceutical
Monday, 11 Jul 2016 

Celyad SA : Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. <4528.T> to develop allogeneic NKR-2 T-cell immunotherapy . Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan . Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories. . Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories . Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million) . Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones .Will also receive double digit royalties based on net sales of licensed product in ONO's territories.  Full Article

ONO PHARMACEUTICAL raises consolidated full-year outlook for FY 2016
Tuesday, 2 Feb 2016 

ONO PHARMACEUTICAL CO LTD:Says the company increased the consolidated full-year outlook for revenue to 156,000 mln yen from 144,500 mln yen, for the fiscal year ending March 31, 2016.Operating profit forecast increased to 24,000 mln yen from 15,200 mln yen.Net profit forecast increased to 18,600 mln yen from 13,100 mln yen.Earnings per share increased to 175.46 yen from 123.58 yen.Comments the increased sales of core products as the main reason for the forecast.  Full Article

BRIEF-Ono Pharmaceutical completes retirement of treasury shares

* Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31